CorMedix Inc(CRMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | 3.72 | EPS (ttm) | 2.1 | Insider Own | 8.19% | Shs Outstand | 77.7M | Perf Week | -7.62% |
| Market Cap | 0.61B | Forward P/E | 130.42 | EPS next Y | -87.7% | Insider Trans | - | Shs Float | 71.6M | Perf Month | 10.21% |
| Enterprise Value | 0.50B | PEG | - | EPS next Q | -0.1 | Inst Own | 57.09% | Short Float | 22.4% | Perf Quarter | -12.67% |
| Income | 0.19B | P/S | 1.32 | EPS this Y | -76.08% | Inst Trans | 3.04% | Short Ratio | 12.7 | Perf Half Y | 22.27% |
| Sales | 0.46B | P/B | 1.32 | EPS next 5Y | - | ROA | 32.36% | Short Interest | 16.03M | Perf YTD | -32.72% |
| Book/sh | 5.93 | P/C | 2.37 | EPS past 3/5Y | - | ROE | 54.93% | 52W High | -41.34% ($13.34) | Perf Year | -40.22% |
| Cash/sh | 3.3 | P/FCF | 2.44 | Sales past 3/5Y | 1582.83% 319.75% | ROIC | 30.89% | 52W Low | 27.76% ($6.12) | Perf 3Y | 100.64% |
| Dividend Est. | - | EV/EBITDA | 1.97 | EPS Y/Y TTM | 210.82% | Gross Margin | 82.78% | Volatility(W/M) | 3.22% 4.69% | Perf 5Y | 69.01% |
| Dividend TTM | - | EV/Sales | 1.08 | Sales Y/Y TTM | 280.5% | Oper. Margin | 46.95% | ATR (14) | 0.33 | Perf 10Y | -12.08% |
| Dividend Ex-Date | - | Quick Ratio | 2.36 | EPS Q/Q | 1.92% | Profit Margin | 40.49% | RSI (14) | 43.49 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.56 | Sales Q/Q | 156.52% | SMA20 | -4.81% ($8.22) | Beta | 1.4 | Target Price | $15.4 |
| Payout | - | Debt/Eq | 0.31 | Earnings | 2026/8/13 | SMA50 | -2.9% ($8.05) | Rel Volume | 0.65 | Prev Close | $7.96 |
| Employees | 191 | LT Debt/Eq | 0.31 | EPS/Sales Surpr. | 21.85% 6.13% | SMA200 | -4.78% ($8.21) | Avg Volume(3M) | 1.26M | Price | $7.82 |
| IPO | 2010/5/13 | Option/Short | Yes/Yes | Trades | 6544 | Volume | 816,700 | Change | -1.7% |
Company
CRMD is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🩺 CorMedix (CRMD) is a U.S. biotech company specializing in the prevention of catheter-related bloodstream infections (CRBSIs). Its flagship product, DefenCath, is a catheter lock solution that combines the antimicrobial agent taurolidine with the anticoagulant heparin, and is used to reduce the risk of infection in hemodialysis patients. CorMedix is an infection-prevention-focused company that holds the first and only antimicrobial catheter lock solution of its kind approved in the United States.
Over the past 1 year, on the lower side
41% below its 1-year high.
CRMD makes money exceptionally well
46.95% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -76.1% this year.
Tap to view numbers
The stock looks undervalued
Trading at 3.7 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +100.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 57.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
RNIN 0.01%
XPH 0.01%
PILL 0.01%
FDLS 0.01%
SBAR 0.01%It ranks #4 in the industry
Based on market cap of $610M.
CRMD $610M PER 3.7
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is CRMD?
CRMD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CRMD?
The market cap of CRMD is approximately $610M, ranking 3,058 within its sector.
What is the P/E ratio of CRMD?
CRMD has a P/E ratio of approximately 3.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for CRMD?
CRMD has recorded a 52-week high of $13.34 and a low of $6.12.
